The purpose of this study is to compare the effects, good or bad of an investigational product, capivasertib added to standard treatments in patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) and your cancer has low levels of a protein called PTEN (or “PTEN deficiency”).

Trial Status
Active, not recruiting
Trial Phase
Phase 3 Drug Trial
Registry Listing
ERM Project ID
Trial contact details
Contact Person
Donna Harvey
What you need to know

Who can take part?

Patients with metastatic hormone-sensitive prostate cancer (mHSPC).

What is involved for you?

Participation in this study may continue for 4.5 years. It will involve seeing the doctor and coordinator for study visits every 2-4 weeks  for physical exams, ECG's, blood tests, tumour assessments (ie-CT scans). You will be required to take oral medicine most days of the study, and do some self assessments of your side effects.

All research clinical trials news

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.



Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Displaying results 1-3 (of 17)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|